Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Celiac Disease, Fibrosis, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TGM2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TGM2 WT & Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed. Includes C277S catalytic dead mutant and W241A GTP-binding defective mutant. |
View TGM2 Products |
| Gene Delivery | TGM2 Premade Lentivirus Full-length ORF for stable fibroblast/epithelial cell lines. CMV or EF1a promoter. |
View TGM2 Products |
| Ortholog Panel | Human / Mouse / Cynomolgus TGM2 Protein For selectivity screening and cross-species toxicology. |
View TGM2 Products |
| Benchmark Ab | Anti-TGM2 Benchmark Control / Monoclonal Antibody High-affinity recombinant positive control for research and diagnostic assays. |
View TGM2 Products |
| Validator | TGM2 siRNA Set For knockdown verification in fibrosis and oncology models. |
View TGM2 Products |
| Related Target A | TGM1 (Transglutaminase 1) Epidermal differentiation; critical selectivity counter-target. |
View TGM1 Products |
| Related Target B | TGM3 (Transglutaminase 3) Hair follicle, neural tissue specificity panel. |
View TGM3 Products |
| Related Target C | F13A1 (Coagulation Factor XIII A chain) Blood transglutaminase, critical for off-target selectivity assays. |
View F13A1 Products |
| Related Target D | FN1 (Fibronectin) Major extracellular interaction partner for TGM2 in matrix remodeling. |
View FN1 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational State Detection (Open vs Closed) | High Purity (>95%) Monomeric Protein verified by SEC-MALS; Suitable for SPR conformational assays. Mutant panels (C277S, W241A) available for mechanism studies. |
| Transglutaminase Family Selectivity | Homolog Panel (TGM1, TGM3, F13A1) strictly verified by Mass Spec; sequence accuracy guaranteed for counter-screening. |
| Cross-Species Pharmacology | Human / Mouse / Cynomolgus TGM2 ortholog proteins available with >95% purity; endotoxin-controlled for in vivo studies. |
| GTPase vs Transglutaminase Activity Discrimination | W241A GTP-binding defective mutant and C277S active site mutant available for functional discrimination. |
| Enzymatic Activity Standardization | Activity-Ready format with calcium-saturated buffer recommendations; theoretical specific activity calculated. |
| Lack of Controls / False Positives | Recombinant positive control antibodies and validated siRNA sets included for precise specificity benchmarking. |
Live TGM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TGM2-targeted therapeutics is intensifying, driven by its validated role in Celiac Disease and emerging roles in tissue fibrosis, aggressive solid tumors, and neurodegeneration. First-generation active-site inhibitors, led by ZED1227 (Zedira/Dr. Falk Pharma), have demonstrated clinical proof-of-concept in celiac disease. The next wave of R&D is targeting highly specific allosteric modulation to avoid off-target toxicity within the transglutaminase family (especially Factor XIII), isoform-selective inhibitors to minimize coagulation risks, and targeted protein degradation (PROTACs) for oncology. Additionally, BBB-penetrant inhibitors are being explored for neurodegenerative indications such as Huntington's disease. Combination strategies leveraging TGM2 inhibition with immune checkpoint inhibitors or chemotherapy are under investigation to overcome tumor microenvironment fibrosis and drug resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (Active Site) | Zedira, Dr. Falk Pharma, Bio-Techne | Celiac Disease, IPF, Renal Fibrosis | Enzymatic Activity & Selectivity Panel (Need high-purity WT & mutant TGM2 plus homolog panel) |
| Small Molecule Inhibitor (Allosteric) | Academic Consortia, Early Biotech | Solid Tumors, Neurodegeneration | Conformational Binding Assay (Need mutant vs WT discrimination; GTP-binding competition assay) |
| Monoclonal Antibodies / Biologics | Various Biotechs, Diagnostic Partners | Fibrosis, Oncology, Autoimmune Diagnostics | Binding/Affinity & Epitope Mapping (Need HEK293-expressed full-length and domain proteins) |
| PROTACs / Degraders | Academic/Early Biotech | Solid Tumors | Degradation Assays (Need stable cell lines via lentivirus and wild-type/mutant target proteins) |